• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

糖尿病患者群体中视力丧失的14年发病率。

The 14-year incidence of visual loss in a diabetic population.

作者信息

Moss S E, Klein R, Klein B E

机构信息

Department of Ophthalmology and Visual Sciences, University of Wisconsin Medical School, Madison, USA.

出版信息

Ophthalmology. 1998 Jun;105(6):998-1003. doi: 10.1016/S0161-6420(98)96025-0.

DOI:10.1016/S0161-6420(98)96025-0
PMID:9627648
Abstract

OBJECTIVE

The purpose of the study was to estimate the 14-year incidence of visual loss in a diabetic population and to examine its relationship to potential risk factors.

DESIGN

Cohort study.

PARTICIPANTS

A population-based sample of younger onset diabetic persons diagnosed younger than 30 years of age and taking insulin (n = 880) were examined at baseline, 4 years, 10 years, and 14 years.

INTERVENTION

Visual acuity (VA) as measured by the Early Treatment Diabetic Retinopathy Study protocol was performed.

MAIN OUTCOME MEASURES

Visual impairment (VI), defined as a VA of 20/40 or worse in the better eye; blindness, defined as a VA of 20/200 or worse in the better eye; and doubling of the visual angle were measured.

RESULTS

Cumulative 14-year incidences of VI, doubling of the visual angle, and blindness were 12.7%, 14.2%, and 2.4%, respectively. In univariate analyses, loss of vision as measured by doubling of the visual angle is associated with older age, longer duration of diabetes, higher glycosylated hemoglobin, higher systolic and diastolic blood pressure, presence of proteinuria, more pack-years smoked, presence of macular edema, and more severe retinopathy. In logistic regression analyses, incidence of doubling of the visual angle is associated independently with retinopathy (odds ratio [OR], 1.07; 95% confidence interval [CI], 1.03, 1.11 for each level), glycosylated hemoglobin (OR, 1.46; 95% CI, 1.28, 1.66 for each 1%), proteinuria (OR, 2.32; 95% CI, 1.39, 3.88 for presence), and age (OR, 1.45; 95% CI, 1.20, 1.75 for 10 years). In addition, a change in glycosylated hemoglobin from baseline to the 4-year examination is associated with loss of vision (OR, 1.15; 95% CI, 1.02, 1.30 for a 1% increase).

CONCLUSIONS

Loss of vision continues to be significant in persons with diabetes. These results suggest that prevention of retinopathy through control of glycemia will have a beneficial effect on visual outcome.

摘要

目的

本研究旨在评估糖尿病患者14年视力丧失的发生率,并探讨其与潜在危险因素的关系。

设计

队列研究。

参与者

以人群为基础,选取年龄小于30岁且正在接受胰岛素治疗的年轻起病糖尿病患者样本(n = 880),在基线、4年、10年和14年时进行检查。

干预措施

按照糖尿病视网膜病变早期治疗研究方案测量视力(VA)。

主要观察指标

视力损害(VI),定义为较好眼的视力为20/40或更差;失明,定义为较好眼的视力为20/200或更差;以及视角加倍情况。

结果

14年VI、视角加倍和失明的累积发生率分别为12.7%、14.2%和2.4%。在单因素分析中,以视角加倍衡量的视力丧失与年龄较大、糖尿病病程较长、糖化血红蛋白水平较高、收缩压和舒张压较高、蛋白尿的存在、吸烟包年数较多、黄斑水肿的存在以及视网膜病变更严重有关。在逻辑回归分析中,视角加倍的发生率独立与视网膜病变(比值比[OR],1.07;95%置信区间[CI],每增加一个级别为1.03,1.11)、糖化血红蛋白(OR,1.46;95%CI,每增加1%为1.28,1.66)、蛋白尿(OR,2.32;95%CI,存在时为1.39,3.88)和年龄(OR,1.45;95%CI,每增加10岁为1.20,1.75)相关。此外,从基线到4年检查时糖化血红蛋白的变化与视力丧失相关(OR,1.15;95%CI,每增加1%为1.02,1.30)。

结论

糖尿病患者的视力丧失仍然很严重。这些结果表明,通过控制血糖来预防视网膜病变将对视力结局产生有益影响。

相似文献

1
The 14-year incidence of visual loss in a diabetic population.糖尿病患者群体中视力丧失的14年发病率。
Ophthalmology. 1998 Jun;105(6):998-1003. doi: 10.1016/S0161-6420(98)96025-0.
2
Ten-year incidence of visual loss in a diabetic population.糖尿病患者群体中视力丧失的十年发病率。
Ophthalmology. 1994 Jun;101(6):1061-70. doi: 10.1016/s0161-6420(94)31217-6.
3
The 25-year incidence of visual impairment in type 1 diabetes mellitus the wisconsin epidemiologic study of diabetic retinopathy.1 型糖尿病的 25 年视力障碍发生率——威斯康星州糖尿病视网膜病变的流行病学研究。
Ophthalmology. 2010 Jan;117(1):63-70. doi: 10.1016/j.ophtha.2009.06.051. Epub 2009 Oct 31.
4
The incidence of vision loss in a diabetic population.糖尿病患者群体中视力丧失的发生率。
Ophthalmology. 1988 Oct;95(10):1340-8. doi: 10.1016/s0161-6420(88)32991-x.
5
The Wisconsin Epidemiologic Study of Diabetic Retinopathy XXIII: the twenty-five-year incidence of macular edema in persons with type 1 diabetes.威斯康星糖尿病视网膜病变流行病学研究XXIII:1型糖尿病患者黄斑水肿的25年发病率
Ophthalmology. 2009 Mar;116(3):497-503. doi: 10.1016/j.ophtha.2008.10.016. Epub 2009 Jan 22.
6
The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XVII. The 14-year incidence and progression of diabetic retinopathy and associated risk factors in type 1 diabetes.威斯康星糖尿病视网膜病变流行病学研究:第十七部分。1型糖尿病患者糖尿病视网膜病变的14年发病率、进展情况及相关危险因素
Ophthalmology. 1998 Oct;105(10):1801-15. doi: 10.1016/S0161-6420(98)91020-X.
7
Epidemiology of Ocular Functions and Diseases in Persons With Diabetes糖尿病患者眼部功能与疾病的流行病学
8
Long-term changes in visual acuity in an older population over a 15-year period: the Blue Mountains Eye Study.在长达 15 年的时间里,老年人群体的视力长期变化:蓝山眼部研究。
Ophthalmology. 2013 Oct;120(10):2091-9. doi: 10.1016/j.ophtha.2013.03.032. Epub 2013 May 30.
9
Blindness in a 25-year follow-up of a population-based cohort of Danish type 1 diabetic patients.对丹麦1型糖尿病患者人群队列进行25年随访后的失明情况。
Ophthalmology. 2009 Nov;116(11):2170-4. doi: 10.1016/j.ophtha.2009.04.043. Epub 2009 Sep 10.
10
The Wisconsin Epidemiologic Study of Diabetic Retinopathy: XXII the twenty-five-year progression of retinopathy in persons with type 1 diabetes.威斯康星糖尿病视网膜病变流行病学研究:XXII 1型糖尿病患者视网膜病变的25年进展情况
Ophthalmology. 2008 Nov;115(11):1859-68. doi: 10.1016/j.ophtha.2008.08.023.

引用本文的文献

1
Targeting Diabetic Retinopathy with Human iPSC-Derived Vascular Reparative Cells in a Type 2 Diabetes Model.在2型糖尿病模型中用人诱导多能干细胞衍生的血管修复细胞治疗糖尿病视网膜病变
Cells. 2025 Aug 30;14(17):1352. doi: 10.3390/cells14171352.
2
Effect of Suprachoroidal Triamcinolone Acetonide on Intraocular Pressure in Macular Edema: A Retrospective Study.脉络膜上腔注射曲安奈德对黄斑水肿眼压的影响:一项回顾性研究
Cureus. 2025 Jan 11;17(1):e77282. doi: 10.7759/cureus.77282. eCollection 2025 Jan.
3
A bibliometric and visualization analysis of electrochemical biosensors for early diagnosis of eye diseases.
用于眼部疾病早期诊断的电化学生物传感器的文献计量与可视化分析
Front Med (Lausanne). 2025 Jan 10;11:1487981. doi: 10.3389/fmed.2024.1487981. eCollection 2024.
4
Intravitreal therapy for the management of diabetic retinopathy: A concise review.玻璃体内注射疗法治疗糖尿病性视网膜病变:简要综述
World J Exp Med. 2024 Dec 20;14(4):99235. doi: 10.5493/wjem.v14.i4.99235.
5
Association between choroidal thickness and diabetic macular edema: a meta-analysis.脉络膜厚度与糖尿病性黄斑水肿的相关性:荟萃分析。
Acta Diabetol. 2024 Aug;61(8):951-961. doi: 10.1007/s00592-024-02306-0. Epub 2024 Jun 10.
6
Machine learning regression algorithms to predict short-term efficacy after anti-VEGF treatment in diabetic macular edema based on real-world data.基于真实世界数据的机器学习回归算法预测糖尿病黄斑水肿抗 VEGF 治疗后的短期疗效。
Sci Rep. 2023 Oct 31;13(1):18746. doi: 10.1038/s41598-023-46021-2.
7
Does HbA1c Level or Glomerular Filtration Rate Affect the Clinical Response to Endothelial Growth Factor Therapy (Ranibizumab or Aflibercept) in Diabetic Macular Edema? A Real-Life Experience.糖化血红蛋白水平或肾小球滤过率是否会影响糖尿病性黄斑水肿患者对内皮生长因子治疗(雷珠单抗或阿柏西普)的临床反应?一项真实病例经验。
Ophthalmol Ther. 2023 Oct;12(5):2657-2670. doi: 10.1007/s40123-023-00758-1. Epub 2023 Jul 28.
8
Visual and Anatomical Outcomes of a Single Intravitreal Dexamethasone in Diabetic Macular Edema: An 8 Year Real-World Study.玻璃体内单次注射地塞米松治疗糖尿病性黄斑水肿的视力及解剖学转归:一项为期8年的真实世界研究
J Clin Med. 2023 Jun 6;12(12):3878. doi: 10.3390/jcm12123878.
9
Ziv-aflibercept in Diabetic Macular Edema: Relation of Subfoveal Choroidal Thickness with Visual and Anatomical Outcomes.阿柏西普治疗糖尿病性黄斑水肿:黄斑中心凹下脉络膜厚度与视力及解剖学转归的关系
J Ophthalmic Vis Res. 2023 Apr 19;18(2):164-169. doi: 10.18502/jovr.v18i2.13182. eCollection 2023 Apr-Jun.
10
Aflibercept monotherapy versus aflibercept with targeted retinal laser to peripheral retinal ischemia for diabetic macular oedema (LADAMO).阿柏西普单药治疗与阿柏西普联合靶向视网膜激光治疗糖尿病黄斑水肿伴外周视网膜缺血(LADAMO)。
Eye (Lond). 2023 Nov;37(16):3417-3422. doi: 10.1038/s41433-023-02525-9. Epub 2023 Apr 17.